Insulin resistance and endothelial dysfunction constitute a common therapeutic target in cardiometabolic disorders

Mediators of Inflammation

Volumn 2016, Issue , 2016, Pages

  Janus, A ^a,b   Szahidewicz Krupska, E ^a,b   Mazur, G ^a   Doroszko, A ^a,b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Wrovasc Integrated Cardiovascular Centre   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; LIPID;

ANGIOGENESIS; ATHEROSCLEROSIS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL SURVIVAL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; GLUCOSE METABOLISM; GLUCOTOXICITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOTOXICITY; METABOLIC SYNDROME X; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CARDIOVASCULAR DISEASES; CHEMISTRY; INFLAMMATION; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; INFLAMMATION; INSULIN; INSULIN RESISTANCE; LIPIDS; MAP KINASE SIGNALING SYSTEM; METABOLIC SYNDROME X; OXIDATIVE STRESS; PHOSPHATIDYLINOSITOL 3-KINASES; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SIGNAL TRANSDUCTION; VASCULAR DISEASES;

EID: 84978732242     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2016/3634948     Document Type: Review

References (93)

1. K. Mather, T. J. Anderson, and S. Verma, "Insulin action in the vasculature: physiology and pathophysiology, " Journal of Vascular Research, vol. 38, no. 5, pp. 415-422, 2001.
2. S. Dimmeler, I. Fleming, B. Fisslthaler, C. Hermann, R. Busse, and A. M. Zeiher, "Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation, " Nature, vol. 399, no. 6736, pp. 601-605, 1999.
3. W. A. Hsueh and R. E. Law, "Insulin signaling in the arterial wall, "The American Journal of Cardiology, vol. 84, no. 1, pp. 21J-24J, 1999.
4. J.-A. Kim, M. Montagnani, K. K. Koh, and M. J. Quon, "Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms, " Circulation, vol. 113, no. 15, pp. 1888-1904, 2006.
5. J. F. Youngren, "Regulation of insulin receptor function, " Cellular and Molecular Life Sciences, vol. 64, no. 7-8, pp. 873-891, 2007.
6. G. Inoue, B. Cheatham, R. Emkey, and C. R. Kahn, "Dynamics of insulin signaling in 3T3-L1 adipocytes. Differential compartmentalization and trafficking of insulin receptor substrate (IRS)-1 and IRS-2, "The Journal of Biological Chemistry, vol. 273, no. 19, pp. 11548-11555, 1998.
7. A. Taguchi and M. F. White, "Insulin-like signaling, nutrient homeostasis, and life span, " Annual Review of Physiology, vol. 70, pp. 191-212, 2008.
8. D. J. Withers, J. S. Gutierrez, H. Towery, et al., "Disruption of IRS-2 causes type 2 diabetes in mice, " Nature, vol. 391, no. 6670, pp. 900-904, 1998.
9. J. Giraud, R. Leshan, Y.-H. Lee, and M. F. White, "Nutrientdependent and insulin-stimulated phosphorylation of insulin receptor substrate-1 on serine 302 correlates with increased insulin signaling, "The Journal of Biological Chemistry, vol. 279, no. 5, pp. 3447-3454, 2004.
10. B. A. Hemmings and D. F. Restuccia, "PI3K-PKB/Akt pathway, " Cold Spring Harbor Perspectives in Biology, vol. 4, no. 9, Article ID a011189, 2012.
11. B. Miao, I. Skidan, J. Yang, et al., "Small molecule inhibition of phosphatidylinositol-3, 4, 5-triphosphate (PIP3) binding to pleckstrin homology domains, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 46, pp. 20126-20131, 2010.
12. M. A. Lawlor and D. R. Alessi, "PKB/Akt: a keymediator of cell proliferation, survival and insulin responses?" Journal of Cell Science, vol. 114, part 16, pp. 2903-2910, 2001.
13. S. H. Snyder and S. R. Jaffrey, "Vessels vivified by Akt acting on NO synthase, " Nature Cell Biology, vol. 1, no. 4, pp. 95-96, 1999.
14. A. Avogaro, M. Albiero, L. Menegazzo, S. de Kreutzenberg, and G. P. Fadini, "Endothelial dysfunction in diabetes: the role of reparatorymechanisms, " Diabetes Care, vol. 34, no. 2, pp. S285-S290, 2011.
15. C. Hermann, B. Assmus, C. Urbich, A. M. Zeiher, and S. Dimmeler, "Insulin-mediated stimulation of protein kinase Akt: a potent survival signaling cascade for endothelial cells, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 2, pp. 402-409, 2000.
16. L. Morbidelli, S. Donnini, and M. Ziche, "Role of nitric oxide in the modulation of angiogenesis, " Current Pharmaceutical Design, vol. 9, no. 7, pp. 521-530, 2003.
17. T. J. McCabe, D. Fulton, L. J. Roman, and W. C. Sessa, "Enhanced electron flux and reduced calmodulin dissociation may explain calcium-independent eNOS activation by phosphorylation, " Journal of Biological Chemistry, vol. 275, no. 9, pp. 6123-6128, 2000.
18. B. D. Manning and L. C. Cantley, "AKT/PKB signaling: navigating downstream, " Cell, vol. 129, no. 7, pp. 1261-1274, 2007.
19. C. M. Taniguchi, B. Emanuelli, and C. R. Kahn, "Critical nodes in signalling pathways: insights into insulin action, " Nature Reviews Molecular Cell Biology, vol. 7, no. 2, pp. 85-96, 2006.
20. H. Rubinfeld and R. Seger, "The ERK cascade: a prototype of MAPK signaling, " Molecular Biotechnology, vol. 31, no. 2, pp. 151-174, 2005.
21. C. Ferri, V. Pittoni, A. Piccoli, et al., "Insulin stimulates endothelin secretion from human endothelial cells and modulates its circulating levels in vivo, " The Journal of Clinical Endocrinology &Metabolism, vol. 80, no. 3, pp. 829-835, 1995.
22. C. Rask-Madsen and C. R. Kahn, "Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 9, pp. 2052-2059, 2012.
23. K. Cusi, K. Maezono, A. Osman, et al., "Insulin resistance differentially affects the PI 3-kinase-andMAP kinase-mediated signaling in human muscle, " Journal of Clinical Investigation, vol. 105, no. 3, pp. 311-320, 2000.
24. M. S. Brown and J. L. Goldstein, "Selective versus total insulin resistance: a pathogenic paradox, " Cell Metabolism, vol. 7, no. 2, pp. 95-96, 2008.
25. R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon, "Cardiovascular actions of insulin, " Endocrine Reviews, vol. 28, no. 5, pp. 463-491, 2007.
26. N. Ouchi, J. L. Parker, J. J. Lugus, and K. Walsh, "Adipokines in inflammation andmetabolic disease, "Nature Reviews Immunology, vol. 11, no. 2, pp. 85-97, 2011.
27. W. A. Hsueh and M. J. Quinones, "Role of endothelial dysfunction in insulin resistance, "The American Journal of Cardiology, vol. 92, no. 4, pp. 10J-17J, 2003.
28. M. Montagnani, I. Golovchenko, I. Kim, et al., "Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells, " The Journal of Biological Chemistry, vol. 277, no. 3, pp. 1794-1799, 2002.
29. J. Davignon and P. Ganz, "Role of endothelial dysfunction in atherosclerosis, " Circulation, vol. 109, no. 23, pp. III27-III32, 2004.
30. M. M. Hartge, T. Unger, and U. Kintscher, "The endothelium and vascular inflammation in diabetes, " Diabetes and Vascular Disease Research, vol. 4, no. 2, pp. 84-88, 2007.
31. S. Del Prato, "Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies, " DiabeticMedicine, vol. 26, no. 12, pp. 1185-1192, 2009.
32. B. Musicki, M. F. Kramer, R. E. Becker, and A. L. Burnett, "Inactivation of phosphorylated endothelial nitric oxide synthase (Ser-1177) by O-GlcNAc in diabetes-associated erectile dysfunction, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 33, pp. 11870-11875, 2005.
33. T. A. McGowan, S. R. Dunn, B. Falkner, and K. Sharma, "Stimulation of urinary TGF-β and isoprostanes in response to hyperglycemia in humans, " Clinical Journal of the American Society of Nephrology, vol. 1, no. 2, pp. 263-268, 2006.
34. I. Gabriely, X. M. Yang, J. A. Cases, X. H. Ma, L. Rossetti, and N. Barzilai, "Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway, " Atherosclerosis, vol. 160, no. 1, pp. 115-122, 2002.
35. D. L. Price, P. M. Rhett, S. R. Thorpe, and J. W. Baynes, "Chelating activity of advanced glycation end-product inhibitors, " Journal of Biological Chemistry, vol. 276, no. 52, pp. 48967-48972, 2001.
36. D. R. Sell, R. H. Nagaraj, S. K. Grandhee, et al., "Pentosidine: a molecular marker for the cumulative damage to proteins in diabetes, aging, and uremia, " Diabetes/Metabolism Reviews, vol. 7, no. 4, pp. 239-251, 1991.
37. J. L. Wautier and P. J. Guillausseau, "Advanced glycation end products, their receptors and diabetic angiopathy, " Diabetes and Metabolism, vol. 27, no. 5, pp. 535-542, 2001.
38. M. C. Gage, N. Y. Yuldasheva, H. Viswambharan, et al., "Endothelium-specific insulin resistance leads to accelerated atherosclerosis in areas with disturbed flow patterns: a role for reactive oxygen species, " Atherosclerosis, vol. 230, no. 1, pp. 131-139, 2013.
39. N. J. Hancer, W. Qiu, C. Cherella, Y. Li, K. D. Copps, and M. F. White, "Insulin and metabolic stress stimulate multisite serine/threonine phosphorylation of insulin receptor substrate and inhibit tyrosine phosphorylation, " Journal of Biological Chemistry, vol. 289, no. 18, pp. 12467-12484, 2014.
40. M. Kaplan, M. Aviram, and T. Hayek, "Oxidative stress and macrophage foam cell formation during diabetes mellitus-induced atherogenesis: role of insulin therapy, " Pharmacology &Therapeutics, vol. 136, no. 2, pp. 175-185, 2012.
41. A. M. Briones, R. Aras-Lopez, M. J. Alonso, and M. Salaices, "Small artery remodeling in obesity and insulin resistance, " Current Vascular Pharmacology, vol. 12, no. 3, pp. 427-437, 2014.
42. K. Van Puyvelde, T. Mets, R. Njemini, I. Beyer, and I. Bautmans, "Effect of advanced glycation end product intake on inflammation and aging: a systematic review, " Nutrition Reviews, vol. 72, no. 10, pp. 638-650, 2014.
43. G. Berg, L. Schreier, and V. Miksztowicz, "Circulating and adipose tissue matrix metalloproteinases in cardiometabolic risk environments: pathophysiological aspects, "HormoneMolecular Biology and Clinical Investigation, vol. 17, no. 2, pp. 79-87, 2014.
44. A. R. Wende, J. D. Symons, and E. D. Abel, "Mechanisms of lipotoxicity in the cardiovascular system, " CurrentHypertension Reports, vol. 14, no. 6, pp. 517-531, 2012.
45. H. Li, H. Li, Y. Bao, X. Zhang, and Y. Yu, "Free fatty acids induce endothelial dysfunction and activate protein kinase C and nuclear factor-κB pathway in rat aorta, " International Journal of Cardiology, vol. 152, no. 2, pp. 218-224, 2011.
46. T. Inoguchi, P. Li, F. Umeda, et al., "High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells, " Diabetes, vol. 49, no. 11, pp. 1939-1945, 2000.
47. M. Mathew, E. Tay, and K. Cusi, "Elevatedplasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects, " Cardiovascular Diabetology, vol. 9, article 9, 2010.
48. R. G. Baker, M. S. Hayden, and S. Ghosh, "NF-κB, inflammation, and metabolic disease, " Cell Metabolism, vol. 13, no. 1, pp. 11-22, 2011.
49. S. E. Kahn, R. L. Hull, and K. M. Utzschneider, "Mechanisms linking obesity to insulin resistance and type 2 diabetes, " Nature, vol. 444, no. 7121, pp. 840-846, 2006.
50. K. H. Jung, H. S. Choi, D. H. Kimet al., "Epigallocatechin gallate stimulates glucose uptake through the phosphatidylinositol 3-kinase-mediated pathway in L6 rat skeletalmuscle cells, " Journal of Medicinal Food, vol. 11, no. 3, pp. 429-434, 2008.
51. J.-A. Kim, M. Montagnani, K. K. Kwang, and M. J. Quon, "Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms, " Circulation, vol. 113, no. 15, pp. 1888-1904, 2006.
52. X.-X. Zheng, Y.-L. Xu, S.-H. Li, X.-X. Liu, R. Hui, and X.-H. Huang, "Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-analysis of 14 randomized controlled trials, " The American Journal of Clinical Nutrition, vol. 94, no. 2, pp. 601-610, 2011.
53. S. Rizza, R. Muniyappa, M. Iantorno, et al., "Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome, " Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 5, pp. E782-E792, 2011.
54. K. M. Munir, S. Chandrasekaran, F. Gao, and M. J. Quon, "Mechanisms for food polyphenols to ameliorate insulin resistance and endothelial dysfunction: therapeutic implications for diabetes and its cardiovascular complications, " American Journal of Physiology-Endocrinology and Metabolism, vol. 305, no. 6, pp. E679-E686, 2013.
55. J. Uribarri, W. Cai, M. Peppa, et al., "Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging, " Journals of Gerontology-Series A: Biological Sciences andMedical Sciences, vol. 62, no. 4, pp. 427-433, 2007.
56. H. Vlassara, W. Cai, J. Crandall, et al., "Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 24, pp. 15596-15601, 2002.
57. N. J. Kellow and G. S. Savige, "Dietary advanced glycation end-product restriction for the attenuation of insulin resistance, oxidative stress and endothelial dysfunction: a systematic review, " European Journal of Clinical Nutrition, vol. 67, no. 3, pp. 239-248, 2013.
58. F. Sofi, R. Abbate, G. F. Gensini, and A. Casini, "Accruing evidence on benefits of adherence to theMediterranean diet on health: an updated systematic review and meta-analysis, " The American Journal of Clinical Nutrition, vol. 92, no. 5, pp. 1189-1196, 2010.
59. E. Koloverou, K. Esposito, D. Giugliano, and D. Panagiotakos, "The effect ofMediterranean diet on the development of type 2 diabetes mellitus: a meta-analysis of 10 prospective studies and 136, 846 participants, " Metabolism: Clinical and Experimental, vol. 63, no. 7, pp. 903-911, 2014.
60. M. Bouchonville, R. Armamento-Villareal, K. Shah, et al., "Weight loss, exercise or both and cardiometabolic risk factors in obese older adults: results of a randomized controlled trial, " International Journal of Obesity, vol. 38, no. 3, pp. 423-431, 2014.
61. K. Esposito, M. I. Maiorino, M. Petrizzo, G. Bellastella, and D. Giugliano, "The effects of a Mediterranean diet on the need for diabetes drugs and remission of newly diagnosed type 2 diabetes: follow-up of a randomized trial, " Diabetes Care, vol. 37, no. 7, pp. 1824-1830, 2014.
62. A. K. F. Wong, A. D. Struthers, A. M. J. Choy, and C. C. Lang, "Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones, " Heart Failure Clinics, vol. 8, no. 4, pp. 539-550, 2012.
63. W. A. Hsueh and R. E. Law, "PPARγ and atherosclerosis effects on cell growth andmovement, "Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 12, pp. 1891-1895, 2001.
64. J. A. Polikandriotis, L. J. Mazzella, H. L. Rupnow, and C. M. Hart, "Peroxisome proliferator-activated receptor γ ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor γ-dependent mechanisms, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1810-1816, 2005.
65. A. Natali and E. Ferrannini, "Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review, " Diabetologia, vol. 49, no. 3, pp. 434-441, 2006.
66. B. J. Davis, Z. Xie, B. Viollet, and M.-H. Zou, "Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase, " Diabetes, vol. 55, no. 2, pp. 496-505, 2006.
67. M. R. Owen, E. Doran, and A. P. Halestrap, "Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain, " The Biochemical Journal, vol. 348, no. 3, pp. 607-614, 2000.
68. M. Foretz, B. Guigas, L. Bertrand, M. Pollak, and B. Viollet, "Metformin: from mechanisms of action to therapies, " Cell Metabolism, vol. 20, no. 6, pp. 953-966, 2014.
69. D. Dicker, "DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors, " Diabetes Care, vol. 34, supplement 2, pp. S276-S278, 2011.
70. J. E. Campbell and D. J. Drucker, "Pharmacology, physiology, and mechanisms of incretin hormone action, " Cell Metabolism, vol. 17, no. 6, pp. 819-837, 2013.
71. International Nonproprietary Names for Pharmaceutical Substances (INN), "Recommended INN: list 61, " WHO Drug Information, vol. 23, no. 1, p. 66f, 2009.
72. J. R. Ussher and D. J. Drucker, "Cardiovascular biology of the incretin system, " Endocrine Reviews, vol. 33, no. 2, pp. 187-215, 2012.
73. O. Erdogdu, D. Nathanson, A. Sjoholm, T. Nystrom, and Q. Zhang, "Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA-and PI3K/Aktdependent pathways and requires GLP-1 receptor, " Molecular and Cellular Endocrinology, vol. 325, no. 1-2, pp. 26-35, 2010.
74. H. Liu, A. E. Dear, L. B. Knudsen, and R. W. Simpson, "A longacting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules, " Journal of Endocrinology, vol. 201, no. 1, pp. 59-66, 2009.
75. M. Arakawa, T. Mita, K. Azuma, et al., "Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4, " Diabetes, vol. 59, no. 4, pp. 1030-1037, 2010.
76. Z. Shah, T. Kampfrath, J. A. Deiuliis, et al., "Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis, " Circulation, vol. 124, no. 21, pp. 2338-2349, 2011.
77. I. Hadjiyanni, K. A. Siminovitch, J. S. Danska, and D. J. Drucker, "Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells, " Diabetologia, vol. 53, no. 4, pp. 730-740, 2010.
78. M. Kassan, M. Galan, M. Partyka, M. Trebak, and K. Matrougui, "Interleukin-10 released by CD4+CD25+ Natural regulatory T cells improves microvascular endothelial function through inhibition of NADPH oxidase activity in hypertensive mice, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 11, pp. 2534-2542, 2011.
79. A. R. Aroor, J. R. Sowers, S. B. Bender, et al., "Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistantmale Zucker obese rats, " Endocrinology, vol. 154, no. 7, pp. 2501-2513, 2013.
80. W. B. White, C. P. Cannon, S. R. Heller, et al., "Alogliptin after acute coronary syndrome in patients with type 2 diabetes, " The New England Journal ofMedicine, vol. 369, no. 14, pp. 1327-1335, 2013.
81. B. M. Scirica, D. L. Bhatt, E. Braunwald, et al., "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus, "The New England Journal ofMedicine, vol. 369, no. 14, pp. 1317-1326, 2013.
82. L. Eriksson and T. Nystrom, "Antidiabetic agents and endothelial dysfunction-beyond glucose control, " Basic and Clinical Pharmacology and Toxicology, vol. 117, no. 1, pp. 15-25, 2015.
83. C. Manrique, G. Lastra, M. Gardner, and J. R. Sowers, "The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress, " Medical Clinics of North America, vol. 93, no. 3, pp. 569-582, 2009.
84. M. E. Pueyo, W. Gonzalez, A. Nicoletti, F. Savoie, J.-F. Arnal, and J.-B. Michel, "Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-κB activation induced by intracellular oxidative stress, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 3, pp. 645-651, 2000.
85. J. M. Perkins and S. N. Davis, "The renin-angiotensinaldosterone system: a pivotal role in insulin sensitivity and glycemic control, " Current Opinion in Endocrinology, Diabetes and Obesity, vol. 15, no. 2, pp. 147-152, 2008.
86. G. Tocci, F. Paneni, F. Palano, et al., "Angiotensin-converting enzyme inhibitors, angiotensin ii receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials, " American Journal of Hypertension, vol. 24, no. 5, pp. 582-590, 2011.
87. A. J. Scheen, "Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials, " Diabetes & Metabolism, vol. 30, no. 6, pp. 487-496, 2004.
88. J. Bosch, S. Yusuf, H. C. Gerstein, et al., "Effect of ramipril on the incidence of diabetes, "TheNew England Journal ofMedicine, vol. 355, no. 15, pp. 1551-1562, 2006.
89. G. B. J. Mancini, G. C. Henry, C. Macaya, et al., "Angiotensinconverting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: The TREND (Trial on Reversing Endothelial Dysfunction) study, " Circulation, vol. 94, no. 3, pp. 258-265, 1996.
90. K. K. Koh, M. J. Quon, S. H. Han, et al., "Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients, " Circulation, vol. 110, no. 24, pp. 3687-3692, 2004.
91. N. Suksomboon, N. Poolsup, and T. Prasit, "Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes, " Journal of Clinical Pharmacy andTherapeutics, vol. 37, no. 3, pp. 319-327, 2012.
92. P. A. Economides, A. Caselli, E. Tiani, L. Khaodhiar, E. S. Horton, and A. Veves, "The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes, " Journal of Clinical Endocrinology andMetabolism, vol. 89, no. 2, pp. 740-747, 2004.
93. A. Keech, R. J. Simes, P. Barter, et al., "Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, " The Lancet, vol. 366, no. 9500, pp. 1849-1861, 2005.